Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.54 |
| ▸ | ACACA | Q13085 | 5/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170379 | 0.92 | ACACB (0.53) | ACACBACACAMAPTLMNAKDM4E | |
| SCHEMBL550912 | 0.91 | ACACB (0.53) | ACACBACACAMAPTLMNASMN1; SMN2 | |
| SCHEMBL10170392 | 0.91 | ACACB (0.55) | ACACBACACAMAPTLMNASMN1; SMN2 | |
| SCHEMBL551729 | 0.90 | ACACB (0.53) | ACACBACACAMAPTLMNAKDM4E | |
| SCHEMBL552021 | 0.88 | ACACB (0.50) | ACACBACACAMAPTLMNASMN1; SMN2 | |
| SCHEMBL10170404 | 0.88 | ACACB (0.51) | ACACBACACAMGLLTACR3 | |
| SCHEMBL551053 | 0.86 | ACACB (0.50) | ACACBACACAMGLLMAPTLMNA | |
| SCHEMBL10170395 | 0.84 | ACACB (0.52) | ACACBACACAMGLLMAPTLMNA | |
| SCHEMBL10170259 | 0.84 | ACACB (0.52) | ACACBACACAMGLLMAPTLMNA | |
| SCHEMBL10170114 | 0.83 | ACACB (0.46) | ACACBACACAMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | ACACA, ACAT1, ACACB | ACACB 3/4885ACACA 1/4885MGLL 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.